Valneva SE revenue breakdown overview

Valneva SE revenue for the last year amounted to 169.64 M USD, the most of which — 169.66 M USD — came from its highest performing source at the moment, Development and Commercialization of Prophylactic Vaccines. The greatest contribution to the revenue figure was made by United States — last year it brought Valneva SE 36.38 M USD, and the year before that — -25.48 M USD.